Curacle Co Ltd
KOSDAQ:365270
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Curacle Co Ltd
Accounts Receivables
Curacle Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Curacle Co Ltd
KOSDAQ:365270
|
Accounts Receivables
₩1.2B
|
CAGR 3-Years
95%
|
CAGR 5-Years
125%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩2T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accounts Receivables
₩1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Receivables
₩80.8m
|
CAGR 3-Years
332%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩37.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
81%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Receivables
₩59.1B
|
CAGR 3-Years
2 371%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Curacle Co Ltd
Glance View
Curacle Co., Ltd. is engaged in the business of research and experimental development on medical sciences and pharmacy. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2021-07-22. The firm researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.
See Also
What is Curacle Co Ltd's Accounts Receivables?
Accounts Receivables
1.2B
KRW
Based on the financial report for Dec 31, 2024, Curacle Co Ltd's Accounts Receivables amounts to 1.2B KRW.
What is Curacle Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
125%
Over the last year, the Accounts Receivables growth was 0%. The average annual Accounts Receivables growth rates for Curacle Co Ltd have been 95% over the past three years , 125% over the past five years .
